The NanoCont^TM drug development platform

MAA Laboratories’ NanoCont^TM technology is a scalable and broadly applicable drug development platform designed to create nanoformulated drug products with clinically and commercially significant improvements in drug performance. The NanoCont^TM platform can be utilized to create advanced medicines for both marketed products and investigational compounds and is compatible with all clinical indications and dosage forms.

Intellectual Property Protection

For lifecycle management of proven drug products, the NanonCont^TM technology can be used to reformulate marketed products in a manner that resolves known drug performance liabilities and creates new intellectual property protection. According to clinical and commercial needs, we use the NanoCont^TM platform in combination with customized, patentable formulations to create innovative pharmaceutical products with tailor-made improvements in drug performance. For investigational compounds, the NanoCont^TM technology can be used to overcome hurdles related to low solubility and poor bioavailability to ensure consistent dosing and facilitate the development of promising pipeline compounds at preclinical and clinical stages.

How the NanoCont^TM Technology Works

The NanoCont^TM technology is a reformulation process that mechanically grinds pharmaceutical crystals to submicron sizes and stabilizes the resulting “nanocrystals” using a patented polymer-coating process. The nanosized pharmaceutical crystals generated using this technology have a high surface area to volume ratio, which increases the dissolution rate and solubility of poorly soluble drugs and makes them suitable for any dosage form.

Drug development using the NanoCont^TM platform proceeds by creating a customized formulation that is specifically designed to meet the clinical and commercial needs of the final drug product. Nanoformulated pharmaceuticals developed using the NanoCont^TM technology are associated with a number of clinical and commercial benefits, including:

• Increased therapeutic efficiency
• Increased solubility and bioavailability
• Restored dose proportionality
• Reduced or eliminated food effects
• Reduced patient variability and increased compliance
• Mitigated or eliminated undesirable side effects
• Enhanced targeted and controlled-release drug delivery
• Change of dosage form for better market value of the product (i.e. changing from subcutaneous to tablets or capsules)